- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Moore named Iridex interim president, CEO
William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.
Mountain View, CA-William M. Moore has been named interim president and chief executive officer (CEO) of Iridex Corp. Moore succeeds Dominik Beck, whose employment with the company ceased Aug. 24.
Moore will continue to serve as chairman of the Iridex board of directors during his tenure as interim CEO. He has served as a director of the company since September 2007.
Moore co-founded Natus Medical Inc. in 1990 and served as CEO until 1993. He still serves on the Natus board of directors. Moore also served as a consultant to BlueLine Partners, a private equity firm and investor in Iridex, from February 2004 until June 2008.
Iridex also announced that the board has appointed James Mackaness as chief operating officer, effective immediately. He will continue to serve in his role as the company’s chief financial officer.
In assuming the president and CEO role, Moore indicated that he will lead Iridex’s strategic direction and execution to increase shareholder value, whereas Mackaness will assume more day-to-day operational responsibilities.
For more articles in this issue of Ophthalmology Times eReport, click here.
